Viemed Healthcare

VMD-T

Analysis and Opinions about VMD-T

Signal
Opinion
Expert
COMMENT
COMMENT
October 7, 2019
It broke above $3.20 and so far it looks okay, but this trades at low volumes.
It broke above $3.20 and so far it looks okay, but this trades at low volumes.
Keith Richards
Portfolio Manager, ValueTrend Wealth Management
Price
$9.690
Owned
Unknown
PAST TOP PICK
PAST TOP PICK
September 23, 2019
(A Top Pick Sep 24/18, Up 44%) He got stopped out, a mistake. Very profitable, no debt. But they had concentration risk--they need to diversify their customer base. He might buy them back.
Viemed Healthcare (VMD-T)
September 23, 2019
(A Top Pick Sep 24/18, Up 44%) He got stopped out, a mistake. Very profitable, no debt. But they had concentration risk--they need to diversify their customer base. He might buy them back.
Jason Del Vicario
Portfolio Manager, HollisWealth
Price
$9.280
Owned
No
TOP PICK
TOP PICK
May 29, 2019
They are in the non-evasive respiratory product market for COPD. Their recent earnings showed 45% increase in revenues. Trades at 20 times earnings, but he thinks they can continue to grow into that. Yield 0%. (Analysts’ price target is $12.50)
They are in the non-evasive respiratory product market for COPD. Their recent earnings showed 45% increase in revenues. Trades at 20 times earnings, but he thinks they can continue to grow into that. Yield 0%. (Analysts’ price target is $12.50)
Don Lato
President, Padlock Investment Management
Price
$9.480
Owned
Yes
WAIT
WAIT
May 17, 2019
They make breathing masks for sleep apnea patients. Earnings are forecast to $0.35 per share growing to $0.60 next year. A reasonable multiple then.
They make breathing masks for sleep apnea patients. Earnings are forecast to $0.35 per share growing to $0.60 next year. A reasonable multiple then.
Robert McWhirter
President, Selective Asset Management
Price
$9.120
Owned
No
BUY
BUY
May 1, 2019
Have enjoyed 25% margins. They faced speculation of increasing competition, which pressured the stock, so VMD replied that that competition lies years ahead and won't affect them. This trades at a decent 12x next year's earnings. Once VMD lists in the US, their stock price will jump up.
Have enjoyed 25% margins. They faced speculation of increasing competition, which pressured the stock, so VMD replied that that competition lies years ahead and won't affect them. This trades at a decent 12x next year's earnings. Once VMD lists in the US, their stock price will jump up.
Bruce Campbell (2)
President & Portfolio Manager, Stone Castle Investment Management Inc.
Price
$7.800
Owned
Yes
WEAK BUY
WEAK BUY
April 17, 2019
Small company. Market cap around $250 mill. Not very followed. Decent growth on the revenue side of around 40%. Still have to spend that money. The regulatory issues are big. Very competitive space. But they are very good at it.
Small company. Market cap around $250 mill. Not very followed. Decent growth on the revenue side of around 40%. Still have to spend that money. The regulatory issues are big. Very competitive space. But they are very good at it.
Kim Bolton
President and Portfolio Manager, Black Swan Dexteritas
Price
$7.350
Owned
No
STRONG BUY
STRONG BUY
April 4, 2019
He almost made it a Top Pick this time. It is a great company and he continues to love it. They were a former sleep management company and are now in the sleep apnea and oxygen space. He adds when the stock sells off. Over time it will continue to higher until it gets taken out.
He almost made it a Top Pick this time. It is a great company and he continues to love it. They were a former sleep management company and are now in the sleep apnea and oxygen space. He adds when the stock sells off. Over time it will continue to higher until it gets taken out.
Bruce Campbell (2)
President & Portfolio Manager, Stone Castle Investment Management Inc.
Price
$7.010
Owned
Yes
COMMENT
COMMENT
January 21, 2019
Took a beating from $8 to $4 upon news about a regulatory change that effected their medical products. He sold his shares. They rely on medicaid and Medicare, but he'd rather see them diversify their revenue base (which they're talking about doing). Good managers, though; he's met them. VMD was too volatile for him. If you own this and can stomach this volatility, VMD will eventually supply a good return.
Viemed Healthcare (VMD-T)
January 21, 2019
Took a beating from $8 to $4 upon news about a regulatory change that effected their medical products. He sold his shares. They rely on medicaid and Medicare, but he'd rather see them diversify their revenue base (which they're talking about doing). Good managers, though; he's met them. VMD was too volatile for him. If you own this and can stomach this volatility, VMD will eventually supply a good return.
Jason Del Vicario
Portfolio Manager, HollisWealth
Price
$5.360
Owned
No
BUY
BUY
October 4, 2018

They are an interesting company, spun out of the PHM-X group. They have been executing very well. There was a study that looked at what happens when people are closely monitored and it was very in favour in terms of what Biomed does. This is home monitoring of the COPD disease so they can push them out of hospitals sooner. They were growing at 20% per year organically. He continues to own it. PHM-X also looks really attractive now.

They are an interesting company, spun out of the PHM-X group. They have been executing very well. There was a study that looked at what happens when people are closely monitored and it was very in favour in terms of what Biomed does. This is home monitoring of the COPD disease so they can push them out of hospitals sooner. They were growing at 20% per year organically. He continues to own it. PHM-X also looks really attractive now.

Bruce Campbell (2)
President & Portfolio Manager, Stone Castle Investment Management Inc.
Price
$7.110
Owned
Yes
TOP PICK
TOP PICK
September 24, 2018

They're the number three player in U.S. respiratory providers. They were spun out of Patient Home Monitoring. 30% ROE. As long as they execute and grow organically, their stock price will rise in 1-2 years. (no dividend, Anaylsts' price target: $9.75)

Viemed Healthcare (VMD-T)
September 24, 2018

They're the number three player in U.S. respiratory providers. They were spun out of Patient Home Monitoring. 30% ROE. As long as they execute and grow organically, their stock price will rise in 1-2 years. (no dividend, Anaylsts' price target: $9.75)

Jason Del Vicario
Portfolio Manager, HollisWealth
Price
$6.450
Owned
Yes
BUY
BUY
July 24, 2018

Provides breathing masks and other respiratory support services. He expects significant growth and sees it as reasonably priced relative to projected earnings.

Provides breathing masks and other respiratory support services. He expects significant growth and sees it as reasonably priced relative to projected earnings.

Robert McWhirter
President, Selective Asset Management
Price
$4.530
Owned
No
Showing 1 to 11 of 11 entries
  • «
  • 1
  • »